Compare AbCellera Biologics Inc (ABCL) vs Nutanix Inc (NTNX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Nutanix Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Nutanix Inc trades at $53.52 (market cap $14.53B). The key difference: Nutanix Inc is far larger — about 6.2× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | NTNX | |
|---|---|---|
Market Cap | $2.35B | $14.53B |
Sector | Health | Technology |
52-Week High | $8.12 | $81.12 |
52-Week Low | $2.78 | $34.41 |
Enterprise Value | $1.99B | $14.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Nutanix (NTNX) trades at $52.42, up 2.22% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with Q3 2026 earnings beating expectations, 87% gross margins, and projected revenue growth to $2.7B in 2026. Recent NVIDIA certification for Unified Storage and expanding enterprise partnerships highlight strategic positioning in hybrid cloud infrastructure.
Outlook remains positive with 62.5% analyst buy ratings and $56.55 consensus target, though elevated P/E ratio of 55.17 and RSI near overbought levels suggest near-term consolidation risk. Key catalysts include AI infrastructure adoption and VMware migration opportunities, while execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
